ArticleThoracic cancer2022
Ureteral metastasis of small cell lung cancer transformed from lung adenocarcinoma: A case report.
Article in Thoracic cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
- Case Report: Transforming small cell lung cancer: two cases report and literature review.Frontiers in oncology · 2025Article
- Ureteral metastasis of small cell lung cancer transformed from lung adenocarcinoma: A case report.Thoracic cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeted therapy offers a new option for patients with advanced lung adenocarcinoma patients. However, long-term targeted therapy may transform lung adenocarcinoma into small cell lung cancer (SCLC). Herein, we report a 48-year-old female patient with pulmonary adenocarcinoma and ureteral metastasis which transformed from adenocarcinoma to SCLC after surgical and targeted therapies. She was diagnosed with invasive adenocarcinoma undergoing the surgery. Two years later recurrence and metastasis occurred and she was given targeted therapy with gefitinib and osimertinib. Two years after targeted therapy, a right ureteral mass (4.9 × 3.7 × 3.8 cm) pathologically diagnosed with SCLC was found, which indicated that the pathological subtype has changed from adenocarcinoma to SCLC. Ultimately, multiple metastases occurred after two cycles of chemotherapy consisting of cis-platinum plus etoposide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.